<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044785</url>
  </required_header>
  <id_info>
    <org_study_id>401.02.001</org_study_id>
    <secondary_id>GCC0121</secondary_id>
    <nct_id>NCT00044785</nct_id>
  </id_info>
  <brief_title>Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors</brief_title>
  <official_title>A Phase I Study of Escalating Doses of CPT-11 and 5fluorouracil (5FU) Plus PN401 With a Fixed Dose of Leucovorin in Patients With Solid Tumor Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wellstat Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wellstat Therapeutics</source>
  <brief_summary>
    <textblock>
      CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for&#xD;
      colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could&#xD;
      increase its therapeutic potential. It is hypothesized that adding PN401 to the CPT-11, 5FU,&#xD;
      leucovorin regimen will reduce toxicity and will allow higher doses of 5FU to be well&#xD;
      tolerated and therefore potentially increase effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2002</start_date>
  <completion_date>March 2004</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Maximum Tolerated Dose</measure>
  </primary_outcome>
  <enrollment>24</enrollment>
  <condition>Solid Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triacetyluridine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>camptosar</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Must be at least 18 years of age;&#xD;
&#xD;
          -  Life expectancy: At least 3 months;&#xD;
&#xD;
          -  Performance status: ECOG of 0 or 1;&#xD;
&#xD;
          -  Histologic or cytologic proof of a solid tumor cancer that is not amenable to curative&#xD;
             surgical resection;&#xD;
&#xD;
          -  Evaluable or measurable disease documented within 4 weeks of the start of treatment;&#xD;
&#xD;
          -  Prior chemotherapy or radiotherapy is allowed if 4 weeks or more have elapsed prior to&#xD;
             starting treatment and patients have recovered from toxicities of prior treatment;&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
        Hematopoietic: ANC = 1500/ul or more, Platelets = 100,000/ul or more, Hemoglobin = 9.5 g/dL&#xD;
        or more, transfusion prior to evaluation is allowed; Hepatic: Bilirubin = 2.0 mg/dL or less&#xD;
        and SGPT(ALT) and SGOT(AST) &lt; 3 x upper limit of normal (&lt; 5 x upper limit of normal if&#xD;
        liver metastases present) Renal: Serum Creatinine &lt; 2.0 mg/dL;&#xD;
&#xD;
          -  Patient has the initiative, geographic proximity, and means to be compliant with the&#xD;
             protocol;&#xD;
&#xD;
          -  Fertile patients (male or female) must agree to use effective contraception;&#xD;
&#xD;
          -  Must be able to swallow and retain tablets.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Major surgery within the four weeks preceding the start of treatment;&#xD;
&#xD;
          -  Serious medical or psychiatric illness that would prevent self-determined informed&#xD;
             consent;&#xD;
&#xD;
          -  Intensive chemotherapy treatment;&#xD;
&#xD;
          -  Infection or antibiotics at the time of screening;&#xD;
&#xD;
          -  Uncontrolled cardiovascular, pulmonary, renal, neurologic, psychiatric, or hepatic&#xD;
             dysfunction;&#xD;
&#xD;
          -  Pregnant or nursing;&#xD;
&#xD;
          -  Pre-existing diarrhea or uncontrolled clinically significant illness other than cancer&#xD;
             (i.e. ulcerative colitis, malabsorption syndrome);&#xD;
&#xD;
          -  Brain metastases that have not been stable for more than 3 months;&#xD;
&#xD;
          -  Known Dihydropyrimidine Dehydrogenase (DPD) deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Maryland, Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>September 4, 2002</study_first_submitted>
  <study_first_submitted_qc>September 5, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>colorectal cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

